Showcasing Phase 2 Clinical Data for Beacon Therapeutics Laru-Zova to Apply Learnings to Phase 3 Trials
Time: 9:30 am
day: Conference Day Two
Details:
- Understanding the success of the subretinal administration of lara-zova to maximize delivery
- Analyzing phase 2 safety and efficacy results of DAWN trial to ensure quality takeaways for future clinical trials
- Discussing the pitfalls and side effects during the phase 2 trials to prevent similar problems during the next clinical trial
